CYP39A1 G204E基因变异与剥脱综合征患者青光眼及盲风险增加的关联
这项回顾性病例研究纳入35例携带CYP39A1 G204E变异的剥脱综合征患者和150例无该变异的剥脱综合征患者,比较盲、剥脱性青光眼及青光眼严重程度指标。携带变异组盲的发生率28.6%高于无变异组5.4%(OR 7.1),剥脱性青光眼比例65.7%高于27.3%(OR 5.1),且峰值眼压更高、垂直杯盘比更大、视野平均偏差更差。
要点
- 携带CYP39A1 G204E变异的剥脱综合征患者盲的发生率为28.6%,无变异者为5.4%(OR 7.1)。
- 携带变异组剥脱性青光眼比例为65.7%,无变异组为27.3%(OR 5.1)。
- 携带变异组峰值眼压更高、垂直杯盘比更大、视野平均偏差更差(P < 0.001)。
核心结论
- 携带CYP39A1 G204E变异的剥脱综合征患者较无任何CYP39A1变异的剥脱综合征患者盲风险显著增加、剥脱性青光眼发生率更高且青光眼更严重。
研究设计与样本
- 回顾性病例研究,纳入35例携带CYP39A1 G204E变异的剥脱综合征患者和150例从日本剥脱综合征队列中随机选取的无任何CYP39A1变异的剥脱综合征患者。
主要发现
- 携带CYP39A1 G204E变异组盲(视力<0.05小数视力)发生10/35(28.6%),无任何CYP39A1变异组为8/150(5.4%),OR 7.1(95%CI 2.7-20.2),P < 0.001。
- 携带CYP39A1 G204E变异组至少一眼有剥脱性青光眼证据者为23/35(65.7%),无任何CYP39A1变异组为41/150(27.3%),OR 5.1(95%CI 2.4-11.4),P < 0.0001。
- 携带CYP39A1 G204E变异组峰值眼压更高、垂直杯盘比更大、视野平均偏差更差(P < 0.001)。
- 携带CYP39A1 G204E变异组需要激光或青光眼手术干预者为18/35(51.4%),无任何CYP39A1变异组为32/150(21.3%),P < 0.001。
关键数值与推荐
- 盲定义为视力<0.05小数视力;携带CYP39A1 G204E变异组盲发生率28.6% vs 无变异组5.4%(OR 7.1,95%CI 2.7-20.2,P < 0.001)。
- 剥脱性青光眼发生率:携带CYP39A1 G204E变异组65.7% vs 无变异组27.3%(OR 5.1,95%CI 2.4-11.4,P < 0.0001)。
- 激光或青光眼手术干预比例:携带CYP39A1 G204E变异组51.4% vs 无变异组21.3%(P < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Carriers of functionally deficient mutations in the CYP39A1 gene have been recently reported to have a 2-fold increased risk of exfoliation syndrome (XFS). The aim of this study was to evaluate the risk of blindness and related clinical phenotypes of XFS patients carrying the loss-of-function CYP39A1 G204E mutation in comparison with XFS patients without any CYP39A1 mutation. DESIGN: Retrospective case study. PARTICIPANTS: A total of 35 patients diagnosed with XFS carrying the CYP39A1 G204E mutation and 150 XFS patients without any CYP39A1 mutation who were randomly selected from the Japanese XFS cohort. METHODS: Two-sided Fisher exact test with an alpha level < 0.05 was used to estimate the significance of the calculated odds ratio (OR) for all categorical measures. Comparisons between groups of subjects were performed using linear mixed effect models with group as random effect and taking possible dependence between eyes within a subject into account. MAIN OUTCOME MEASURES: Primary analysis compared the incidence of blindness (defined as visual acuity [VA] < 0.05 decimal), prevalence of exfoliation glaucoma (XFG), history of glaucoma surgery, and indices of glaucoma severity such as visual field (VF) mean deviation (MD), intraocular pressure (IOP), and vertical cup-disc ratio (CDR) between CYP39A1 G204E carriers and those without any CYP39A1 mutation. RESULTS: The overall risk for blindness was significantly higher in XFS patients carrying the CYP39A1 G204E variant (10/35 [28.6%]) compared with XFS patients without any CYP39A1 mutations (8/150 [5.4%]; odds ratio [OR], 7.1; 95% confidence interval [CI], 2.7-20.2]; P < 0.001). A higher proportion of XFS patients with the CYP39A1 G204E mutation (23/35 [65.7%]) had evidence of XFG in at least 1 eye compared with the comparison group (41/150 [27.3%]; OR, 5.1; 95% CI, 2.4-11.4]; P < 0.0001). Significantly higher peak IOP, larger vertical CDR, and worse VF MD were also found in CYP39A1 G204E variant carriers (P < 0.001). Additionally, patients with the CYP39A1 G204E mutation (18/35 [51.4%]) required more laser or glaucoma surgical interventions compared with those without any CYP39A1 mutation (32/150 [21.3%], P < 0.001). CONCLUSIONS: Patients with XFS carrying the CYP39A1 G204E mutation had significantly increased risk of blindness, higher occurrence of XFG, and more severe glaucoma compared with patients with XFS without any CYP39A1 mutation.
引用
- Bell K, Ozaki M, Mori K, et al. Association of the CYP39A1 G204E Genetic Variant with Increased Risk of Glaucoma and Blindness in Patients with Exfoliation Syndrome. Ophthalmology. 2021. PMID: 34763023. doi:10.1016/j.ophtha.2021.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。